Ilya Pharma Receives Rare Pediatric Disease Designation From US FDA

Ilya Pharma recently announced that it has received a Rare Pediatric Disease Designation by the US FDA.

About SAVI: STING-associated vasculopathy with onset in infancy (SAVI) is caused by Gain-of-function mutations in the STING1 gene, which encodes the transmembrane protein STING (Stimulator of Interferon Genes). This rare disease belongs to a newly defined class of autoinflammatory disorders referred to as type I interferonopathies that typically presents with neonatal or infantile onset of systemic inflammation and small vessel vasculopathies. SAVI disease is associated with marked childhood morbidity and increased mortality, and is characterized by episodes of recurrent fevers, cold-induced skin vasculitis causing rashes which often progress to loss of fingers and toes, as well as ear and nose tissue, and/or interstitial lung disease. The response to conventional immunosuppressive therapies is minimal in SAVI patients, resulting in marked childhood morbidity and increased mortality, which demonstrates an unmet clinical need.

 About emilimogene sigulactibac: The rationale for investigating topical emilimogene sigulactibac (INN), ILP100-Topical for the treatment of skin wounds in patients with SAVI is based on the results from previous published nonclinical and clinical studies showing 1) Accelerated wound healing, 2) Increased numbers of CXCR4-expressing tissue restorative macrophages in injured tissue improve vessel function and tissue restoration, and 3) Potent antimicrobial effects on bacterial wound pathogens, especially multi drug resistant bacteria.

About Rare Pediatric Disease Designation: Rare Pediatric Disease Designation (RPDD) is granted by the FDA for serious or life-threatening diseases affecting fewer than 200,000 people in the United States and in which the serious or life-threatening manifestations primarily affect individuals less than 18 years of age. If a Biologics Licensing Application (BLA) for emilimogene sigulactibac for the treatment of SAVI is approved by the FDA, Ilya Pharma will be eligible to receive a Priority Review Voucher (PRV) that can be redeemed to receive a priority review for any subsequent marketing application, or may be sold or transferred. This program is intended to encourage the development of new drugs and biologics for the treatment of rare pediatric diseases.

“Pediatric patients living with SAVI face a significant unmet medical need with limited treatment options,” said Margareth Jorvid, Head of Regulatory Affairs, Ilya Pharma. “Obtaining Rare Pediatric Disease Designation is another acknowledgement of the serious and life-threatening manifestations of this rare disease, and supports our mission to provide emilimogene sigulactibac as a potential new treatment option.”

About Ilya Pharma – Ilya Pharma is a clinical stage biopharma company, developing novel drug candidates from its proprietary technology platform to clinical proof of concept in relevant patient groups with identified unmet medical needs. The lead drug candidate ILP100 is also known as emilimogene sigulactibac (INN) as recommended by the WHO. The portfolio includes ILP100-Topical for treatment of surgical wounds in diabetic, prediabetic and obese patients especially at risk and diabetic ulcers, and ILP100-Oral to be evaluated as first-line-treatment for patients with immune mediated enterocolitis resulting from cancer treatment with checkpoint inhibitors. For more information, visit www.ilyapharma.se.